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Recent genome-wide association studies of the highly related chronic inflammatory 
bowel diseases (IBD) known as Crohn’s disease (CD) and ulcerative colitis (UC) have 
shown strong evidence of association to the major histocompatibility complex (MHC). 
This region encodes a large number of immunological candidate genes including those 
that encode the human leukocyte antigens (HLA) that present peptide antigens to T 
lymphocytes[1]. Previous studies of this region in IBD have indicated that multiple 
independent associations are likely to exist at HLA genes and non-HLA genes, but lacked 
the statistical power to define the architecture of association and plausible causal alleles 
[2, 3]. To address this, we performed high-density SNP typing of the MHC in >32,000 
patients with IBD, implicating multiple HLA alleles, with a primary role for HLA-
DRB1*01:03 in both CD and UC. Significant differences, however, were observed between 
these two diseases, including a predominant role of class II HLA variants and 
heterozygous advantage observed in UC, suggesting an important role of the adaptive 
immune response to the colonic environment in UC pathogenesis.  
 
 
Meta-analyses of genome-wide association studies (GWAS) have recently shown that CD 
(MIM266600) and UC (MIM191390) share the majority of the 163 known genetic risk factors for 
IBD, with the MHC being one of the notable exceptions [4].  Data from these GWAS, however, 
have had insufficient variant density to define the association signals within the MHC. Targeted 
studies of IBD with higher variant density within the MHC region but with modest sample sizes 
have indicated that multiple independent associations are likely to exist at HLA genes and non-
HLA genes, with the most consistent associations being to HLA class II loci, mainly HLA-DRB1 
and HLA-DQB1, with some reports of association at the HLA-C class I locus and potentially also 
at non-HLA genes [2, 3, 5-8]. In the current study we generated high quality genotypes for 7,406 
SNPs within the MHC region on a total of 18,405 patients with CD, 14,308 patients with UC and 
34,241 controls subjects. Using this SNP data, we imputed and benchmarked the genetic 
variation within the class I (HLA-B, HLA-C, and HLA-A) and class II (HLA-DRB1, HLA-DRB3, 
HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB1) HLA genes at the 
level of classical HLA alleles and amino acid positions (please refer to the Online Methods). 
 
As a first step to defining the nature of the association to CD and UC within the MHC, we 
performed univariate analyses of the SNPs, classical HLA alleles, and HLA amino acids.  These 
analyses revealed a very large number of variants across the MHC region with significant 
association to these phenotypes (Fig. 1), with major peaks of association centered in and 
around the classical HLA genes, suggesting a role for classical HLA alleles in CD and UC risk. 
This observation is consistent with gene-based analyses, which show strong association at the 
HLA genes for both UC and CD (e.g. P<1×10-300 for HLA-DRB1 in UC) (Supplementary Table 
1). In particular, these analyses demonstrated a role of HLA-DRB1 that cannot be attributed to 
other HLA genes, with evidence of residual association in class I and class II regions 
(Supplementary Table 1). In order to be more quantitative, we calculated the variance 
explained by the class I and class II alleles. Whereas the contribution of class I and class II 
alleles are relatively equivalent in CD, not only is the overall impact of HLA on disease risk 
greater in UC, but the alleles in the class II region have nearly three-fold greater impact than 
class I alleles (Fig. 2).  Moreover, these analyses have revealed that classical HLA alleles 
explain three- to ten-fold more of the disease variance than that explained by the index SNPs 
that were previously identified (~3% vs ~0.3% in CD; ~6% vs ~2% in UC) (Fig. 2). 
 
Specifically, in our univariate analyses, the most significant association in CD is to HLA-
DRB1*01:03 (P<4×10-62, OR= 2.53), with a p-value over 10 orders of magnitude more significant 
than the next best associated variants in the region. Importantly, HLA-DRB1*01:03 has an effect 
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in CD which is statistically independent from the other most associated variants in the MHC, as 
shown by reciprocal conditional logistic regression (Supplementary Fig. 1). While the single 
most significant variant in the UC univariate analysis is a non-coding SNP (rs6927022, P<5×10-
153, OR=1.49) near HLA-DQA1, previously identified in the recent meta-analysis of GWAS [4], 
strikingly the next strongest independent association is also to HLA-DRB1*01:03, with a much  
greater OR (P<1×10-120, OR=3.63; Pcond<2×10
-89, OR=3.06) (Supplementary Fig.2).  Reciprocal 
conditioning on HLA-DRB1*01:03 did not abolish the effect seen at rs6927022 (P<9×10-123, 
OR=1.43), indicating that these have mostly statistically independent effects in UC. Taken 
together, our analyses point to HLA-DRB1*01:03 as likely being causal in both diseases, with 
additional causal alleles in the class II and class I regions. Given this observation, it is probable 
that additional alleles within HLA-DRB1 contribute to IBD risk. 
 
We thus examined an HLA-DRB1-centric model and identified seven HLA-DRB1 alleles with 
independent effects on CD risk (study-wide significance threshold of 5×10-6) (Supplementary 
Table 2).  Moreover, when controlling for these seven HLA-DRB1 alleles, we identified only a 
single additional class II allele (HLA-DPA1*01:03) independently associated with CD.  Using the 
same conditional logistic regression framework for the analysis of the class I locus, we identified 
seven class I HLA alleles that are significantly associated with CD, after conditioning on the eight 
class II alleles (Fig. 3 and Supplementary Table 2). This HLA-DRB1-centric model explains 
about 2% of disease variance (Fig. 2). In UC, we identified a total of 12 HLA-DRB1 alleles, 1 
HLA-DPB1 allele and 3 class I alleles (Supplementary Table 3) that can explain the association 
to the MHC and which account for about 5% of disease variance (Fig. 2). 
 
As can be seen in Figure 3, for many of the alleles identified in the HLA-DRB1-centric model, a 
few other candidate alleles in class I or class II can be considered. In particular, multiple HLA-
DRB1 alleles have equivalent associations at HLA-DQA1 and HLA-DQB1 (e.g. HLA-
DQA1*03:01 is equivalent to HLA-DRB1*04 and HLA-DRB1*09 alleles in UC) equally supporting 
a role for genetic variation within HLA-DQA1 and/or HLA-DQB1 in disease susceptibility, 
particularly for UC (Fig. 3).  However, several of the alleles in these models, including HLA-
DRB1*01:03, do not have any such proxies and thus are strong candidates for being causal 
(Fig. 3). Further dissection of these class II correlated signals for identifying potential causal 
alleles may only be feasible in admixed or ethnically diverse populations [9]. Further refinement 
may also be possible by examining the impact of clinical sub-phenotype and associated 
autoimmune co-morbidities on observed associations, although functional studies will be needed 
to infer causality. For the present analysis we were able to assess the impact of colonic vs. non-
colonic inflammation, and found that HLA-DRB1*01:03 is associated with colonic CD and that 
HLA-DRB1*07:01 is associated with the absence of colon involvement (Supplementary Fig. 3), 
in line with previous suggestions [10]. This explains the shared associations for CD and UC at 
HLA-DRB1*01:03 and strongly suggests that this allele is critically involved in determining the 
colonic immune response to local flora. 
 
Given that classical HLA alleles consist of combinations of specific amino acids at multiple 
positions, we tested whether the association to disease could be better explained by single 
amino acid positions. Indeed we observed very strong association signals at many single amino 
acid variants in CD (e.g. five amino acids of HLA-DRβ at positions 67, 70 and 71) and in UC 
(e.g. 4 amino acid variants of HLA-DQα at positions 50 and 53 and 215 and 4 amino acid 
variants in HLA-DRβ at positions 98 and 104) and also performed per position omnibus analyses 
that confirm the predominant association to HLA-DRβ position 11 in UC, as previously reported 
[5], and to HLA-DRβ position 70 in CD (Supplementary Tables 4-5 and Supplementary Fig. 
4). While the hypothesis of a positional effect is appealing, the interpretation of these position-
based tests is not straightforward in the context of likely multiple causal alleles (Supplementary 
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Note on amino acids, Supplementary Table 6 and Supplementary Fig. 5).  Furthermore in 
this study the amino acid-based models did not capture the association at HLA-DRB1 in a more 
parsimonious way than the HLA allele-based models (Supplementary Note on amino acids). 
To further explore the basis for the observed HLA associations, we performed three-dimensional 
protein structure modeling followed by analysis of the electrostatic properties of the binding 
groove of associated (P<10-4) and common (frequency>1%) HLA-DRB1 alleles. These analyses 
suggest that HLA-DR alleles associated with increased risk of UC and CD, share common 
structural and electrostatic properties within or near their peptide binding groove that are largely 
distinct from those of HLA-DR alleles associated with decreased risk of UC and CD (Fig. 4). 
 
While we performed the primary analyses based on a dose effect model, our sample size 
allowed us to investigate the effects further, by testing for non-additive effects. In fact we found 
significant departure from additive effects in UC, but not for CD (Fig 5a-c). Specifically, we found 
evidence of decreased heterozygosity in UC patients for genotyped and imputed variants across 
the MHC and at HLA genes, mostly in class II (Supplementary Tables 7-8). This heterozygote 
advantage could be explained by an enrichment of dominant protective and recessive risk 
alleles[11], that is absent or much less important in CD (Fig. 5 and Supplementary Fig. 6). 
Notably, we also detected multiple overdominant effects in UC, the strongest of which is 
captured by HLA-DRB1*03:01 (Fig. 5, Supplementary Fig. 6-7, and Supplementary Table 9). 
This allele is mostly found on the ancestral haplotype 8.1, a relatively common (~5-10%) 
haplotype that is conserved in European populations and that is implicated in other immune 
diseases [12-14]. The overdominance effect of this haplotype in UC is possibly due to the 
presence of both dominant protective and recessive risk alleles, which would be consistent with 
the reported recessive risk of this haplotype in the UC-related biliary disease primary sclerosing 
cholangitis (Supplementary Fig. 8-9) [15, 16]. Analogous with an infectious paradigm [11], 
these data may suggest that decreased HLA class II heterozygosity may impair the ability to 
appropriately control colonic microbiota in UC.  
 
Although there is a significant challenge in defining the causal alleles for CD and UC in the MHC 
given the LD structure in the region, a number of conclusions can be drawn regardless of the 
models tested.  First, the high density mapping of this region in a large cohort revealed the 
significant contribution of the MHC to disease risk, a contribution that is not apparent in the 
previous GWAS.  Second, for both CD and UC it would appear that variation within HLA genes 
as opposed to variation in other genes within the MHC plays a predominant role in disease 
susceptibility. Third, while the contribution of class I and class II HLA variants to disease risk is 
relatively equivalent in CD, HLA class II variation plays a more important role in UC. Fourth, in 
contrast to the majority of non-MHC susceptibility loci being shared between CD and UC, most 
associated HLA alleles have a predominant role in either CD or UC, with very few having shared 
IBD risk Fig. 6). Finally, the decreased heterozygosity in UC suggests that the ability to 
recognize a broader set of antigens, potentially of colonic microbial origin, is important to mount 
protective immunity. 
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Figure Legends 
 
Figure 1. Primary univariate association analyses of CD and UC. Univariate association 
analysis results for 8,939 SNPs (dark grey) (Supplementary Table 10), 90 2-digit and 138 4-
digit resolution HLA alleles (yellow) (Supplementary Table 11), as well as 741 single amino 
acid variants (red) (Supplementary Table 4) in the MHC region are shown for 18,405 CD cases 
and 14,308 UC cases (with 34,241 common control subjects). Given that previous genetic 
analyses have identified distinct effects in the MHC for CD and UC, with different non-correlated 
alleles identified in each disease, we opted to perform the finemapping analyses for CD and UC 
separately. (a) The primary univariate association analysis in CD reveals over 1,789 markers 
showing study-wide significant association (P<5×10-6) across the MHC, including 32 4-digit 
resolution classical HLA alleles (Fig. 3 and Supplemental Table 2). The single most significant 
variant for CD is HLA-DRB1*01:03 (P=3x10-62, OR= 2.51). (b) The primary univariate 
association analysis in UC reveals over 2,762 markers showing study-wide significant 
association across the MHC, including 50 4-digit resolution classical HLA alleles (Fig. 3 and 
Supplemental Table 3). The single most significant variant for UC is rs6927022 (P=8×10-154, 
OR= 1.49) while the best HLA allele is HLA-DRB1*01:03 (P=3×10-119, OR=3.59). 
 
Figure 2. Variance explained by 4-digit HLA alleles in CD and UC. Proportion of variance 
explained on a logit scale (McKelvey and Zavoina's Pseudo R2, see Online Methods) for 
different models in CD (left) and UC (right). The top boxes show the variance explained by 
previously identified GWAS index SNPs within the MHC[4]. The middle boxes illustrate the 
variance explained by HLA models including all 4-digit alleles of frequency > 0.5% (126 alleles in 
CD and UC) and models restricted to 4-digit alleles within either class I (63 alleles) or class II 
regions (63 alleles), respectively. The Venn diagram illustrates the proportion of variance 
explained that is unique to class I, class II or shared. The bottom boxes indicate the variance 
explained by the proposed HLA models (15 and 16 alleles in CD and UC, respectively). To be 
noted, these estimations of variance explained were performed on the logit scale for practical 
reasons, and should not be directly compared to heritability estimates computed on the 
(Gaussian) liability scale. 
 
Figure 3. Correlated association signals at HLA alleles support potential alternate 
association models for both CD and UC. Equivalence of effect at the different study-wide 
significant associated 4-digit HLA alleles is shown for (a) CD and (b) UC. The structures 
illustrated in the figure are not classically defined haplotype structures, but were identified 
entirely based on the correlation of signal defined through pairwise reciprocal conditional logistic 
regression analyses (see Supplementary tables 2 and 3); although such correlations are 
clearly dependent on the underlying haplotypic structure of the region. Alleles identified as 
primary tags for independent association signals in our HLA-DRB1 focused models are shown in 
light blue boxes, while alternate alleles with equivalent effects are shown in grey boxes. Alleles 
in white boxes show study-wide significant secondary effects that can be explained entirely by 
the selected HLA alleles. Alleles at the HLA-DRB3, -DRB4 and -DRB5 genes were omitted in 
order to simplify the display; many of the alleles at these genes show high frequency and as 
such are correlated to many different alleles (both risk and protective) at the other class II genes. 
Of note, the HLA-DRB4*null allele is the second strongest associated allele in UC (see 
Supplementary table 3). 
 
 
Figure 4. HLA-DR peptide binding groove electrostatic properties and risk of IBD 
The electrostatic potential of all HLA-DR alleles associated with UC or CD, and of all common 
HLA-DR alleles (frequency >1%), was calculated. HLA-DR alleles associated with increased or 
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decreased risk of IBD at study wide-significance level (P< 5×10-6) are shown in dark red or dark 
blue, respectively. Respective risk associations at suggestive level (1×10-4<P<5×10-6) are shown 
in pale red and pale blue. Electrostatic potential comparisons among HLA-DR molecules were 
performed in a pairwise, all-versus-all, fashion (see Online Methods) to produce distance 
matrices that are displayed as symmetrical heatmaps (scale ranges from 0 [identical] to 1 
[maximum difference]). (a) The electrostatic potential in seven regions within the peptide binding 
groove (see Online Methods and Supplementary Fig. 10), which interact with the presented 
peptide, were compared among the HLA-DR alleles and pooled onto a single Euclidian distance 
matrix. The distance-based clustering identifies four clusters, with an enrichment of risk alleles in 
two of these. Comparison of the electrostatic potential at individual peptide binding groove 
regions is shown in Supplementary Fig. 11. (b) Heatmap representing electrostatic potential 
differences among the HLA-DR alleles at a spherical region that encompasses amino acid 
residues 67, 70 and 71 of the HLA-DRβ chain (associated with risk for UC and CD; 
Supplementary Table 11). The distance-based clustering identifies two clusters that correlate 
with directionality of effect in IBD. 
 
Figure 5. Non-additive effect models in CD and UC. Evidence for non-additive effect of 
common variants (frequency >5%) across the MHC tested under a general model of additive 
and dominance effects (Online Methods) in CD (a,b) and UC (c,d). Low frequency variants, 
such as HLA-DRB1*01:03, were excluded from the analyses of non-additive model due to the 
low number of homozygotes. The p-values and directionality for departure from additive effect 
(dominance term) are represented on the y-axis (a,c). Variants showing either higher or lower 
risk than expected for heterozygotes under an additive model are shown on the upper and lower 
part of the plot respectively. HLA alleles and amino acids variants are in yellow and red 
respectively, while SNPs are represented in dark grey. The dotted lines represent the study wide 
significance threshold of 5×10-6, with non-significant variants plotted in less pronounced colors.  
A clear enrichment for lower risk in heterozygotes is observed in UC (c) as suggested by the 
large number of significant negative dominance term (lower part of the plot). This effect is absent 
in CD (a), or much less important. The dominance term OR for common variants is illustrated (y-
axis) versus the additive term (x-axis), giving an overview of the association model (b,d). 
Variants were plotted using the same color code as in (a,c). Protective and risk minor alleles are 
shown on the left and right sides of the plot respectively. Strictly recessive or dominant variants 
are expected to fall on the diagonals, while strictly additive variants lay on or close to the x-axis. 
The y-axis is the expected position for pure over/under dominance. Variants showing evidence 
of overdominance fall in the lower triangle (light blue). In UC, many alleles with non-additive 
effects fall into the bottom left (protective dominant) and bottom right (risk recessive) quadrants 
of the plots, with some being close to the vertical axis in the lower triangle (overdominance) (see 
Supplementary Table 9 for pairwise comparison of HLA-DRB1 alleles in UC). As an example, 
HLA-DRB1*03:01 and HLA-DQB1*02:01 are located between pure overdominance and pure 
recessive risk (Supplementary Fig. 6). These non-additive effects are observed for many 
variants in UC, but are mostly absent in CD (a,b); notable exception being the HLA-B*08 allele 
(Supplementary Fig. 6). 
 
 
Figure 6. Comparison of odds ratio in CD and UC for HLA alleles identified from HLA-
focused models. Odds ratio (OR) from the primary univariate association analyses in CD and 
UC for all alleles identified in the HLA-focused models of CD and/or UC are presented (a). Odds 
ratio for CD and UC are in blue and red respectively; darker colors indicate study-wide 
significant effect (P< 5×10-6), lighter colors indicate nominal significance level (0.05>P≥5×10-6) 
and white indicates non-significance (P≥0.05) (for specific effect and significance values refer to 
Fig. 3 and Supplementary Tables 2 and 3). Allele HLA-B*52:01 is indicated for UC in place of 
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the equivalent HLA-C*12:02 to simplify the display of this shared signal. For the same HLA 
alleles, odds ratio for an IBD analysis are plotted against the odds ratio for the CD versus UC 
analysis with the IBD risk allele as the reference (b). Alleles identified as significant in CD or UC 
only are plotted in blue and red, respectively. Variants identified as significant in both are shown 
in purple, with empty circles representing opposite direction of effect. Shared association signals 
are expected to fall in the upper triangle of the plot. Most variants fall outside of this region, 
highlighting the difference between CD and UC in the MHC (the same representation with all 
MHC variants is available in Supplementary Figure 12).  
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METHODS 
 
Please refer to attached files 
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